![Pharmacodynamic Effects of Vorapaxar in Prior Myocardial Infarction Patients Treated With Potent Oral P2Y12 Receptor Inhibitors With and Without Aspirin: Results of the VORA‐PRATIC Study | Journal of the American Heart Association Pharmacodynamic Effects of Vorapaxar in Prior Myocardial Infarction Patients Treated With Potent Oral P2Y12 Receptor Inhibitors With and Without Aspirin: Results of the VORA‐PRATIC Study | Journal of the American Heart Association](https://www.ahajournals.org/cms/asset/e8dbd127-8716-46c9-ac60-dc5e3af380b5/jah35032-fig-0002.png)
Pharmacodynamic Effects of Vorapaxar in Prior Myocardial Infarction Patients Treated With Potent Oral P2Y12 Receptor Inhibitors With and Without Aspirin: Results of the VORA‐PRATIC Study | Journal of the American Heart Association
![Pharmacodynamic Effects of Vorapaxar in Patients With and Without Diabetes Mellitus: Results of the OPTIMUS-5 Study - ScienceDirect Pharmacodynamic Effects of Vorapaxar in Patients With and Without Diabetes Mellitus: Results of the OPTIMUS-5 Study - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S2452302X19302256-fx1.jpg)
Pharmacodynamic Effects of Vorapaxar in Patients With and Without Diabetes Mellitus: Results of the OPTIMUS-5 Study - ScienceDirect
![Vorapaxar for HIV-associated inflammation and coagulopathy (ADVICE): a randomised, double-blind, placebo-controlled trial - The Lancet HIV Vorapaxar for HIV-associated inflammation and coagulopathy (ADVICE): a randomised, double-blind, placebo-controlled trial - The Lancet HIV](https://www.thelancet.com/cms/attachment/d58729c6-8f74-4057-b307-abe400ae1612/gr1.gif)
Vorapaxar for HIV-associated inflammation and coagulopathy (ADVICE): a randomised, double-blind, placebo-controlled trial - The Lancet HIV
![Vorapaxar-d5 Sulfate | N-[(1R,3aR,4aR,6R,8aR,9S,9aS)-9-[(1E)-2-[5-(3-Fluorophenyl)-2-pyridinyl]ethenyl]dodecahydro-1-methyl-3-oxonaphtho[2,3-c]furan-6-yl]carbamic Acid Ethyl Ester-d5 Sulfate; Sch 530348-d5; | C₂₉H₃₀D₅FN₂O₈S | TRC Vorapaxar-d5 Sulfate | N-[(1R,3aR,4aR,6R,8aR,9S,9aS)-9-[(1E)-2-[5-(3-Fluorophenyl)-2-pyridinyl]ethenyl]dodecahydro-1-methyl-3-oxonaphtho[2,3-c]furan-6-yl]carbamic Acid Ethyl Ester-d5 Sulfate; Sch 530348-d5; | C₂₉H₃₀D₅FN₂O₈S | TRC](https://www.trc-canada.com/prod-img/V758202.png)
Vorapaxar-d5 Sulfate | N-[(1R,3aR,4aR,6R,8aR,9S,9aS)-9-[(1E)-2-[5-(3-Fluorophenyl)-2-pyridinyl]ethenyl]dodecahydro-1-methyl-3-oxonaphtho[2,3-c]furan-6-yl]carbamic Acid Ethyl Ester-d5 Sulfate; Sch 530348-d5; | C₂₉H₃₀D₅FN₂O₈S | TRC
![Vorapaxar | CAS:618385-01-6 | PAR-1 antagonist,potent and orally active | High Purity | Manufacturer BioCrick Vorapaxar | CAS:618385-01-6 | PAR-1 antagonist,potent and orally active | High Purity | Manufacturer BioCrick](https://www.biocrick.com/media/images/struct3D/BCC3996.png)
Vorapaxar | CAS:618385-01-6 | PAR-1 antagonist,potent and orally active | High Purity | Manufacturer BioCrick
![Reflections on Incorporating Vorapaxar in Contemporary Practice: Who Are the Right Patients? | tctmd.com Reflections on Incorporating Vorapaxar in Contemporary Practice: Who Are the Right Patients? | tctmd.com](https://d14d5nk8lue86f.cloudfront.net/s3fs-public/styles/large_slide_teaser/public/2014-09/126195.png?itok=X9n6Z20z)
Reflections on Incorporating Vorapaxar in Contemporary Practice: Who Are the Right Patients? | tctmd.com
![Role for Thrombin Receptor Antagonism With Vorapaxar in Secondary Prevention of Atherothrombotic Events: From Bench to Bedside - Jae Youn Moon, Francesco Franchi, Fabiana Rollini, Dominick J. Angiolillo, 2018 Role for Thrombin Receptor Antagonism With Vorapaxar in Secondary Prevention of Atherothrombotic Events: From Bench to Bedside - Jae Youn Moon, Francesco Franchi, Fabiana Rollini, Dominick J. Angiolillo, 2018](https://journals.sagepub.com/cms/10.1177/1074248417708617/asset/images/large/10.1177_1074248417708617-fig2.jpeg)
Role for Thrombin Receptor Antagonism With Vorapaxar in Secondary Prevention of Atherothrombotic Events: From Bench to Bedside - Jae Youn Moon, Francesco Franchi, Fabiana Rollini, Dominick J. Angiolillo, 2018
![Platelet thrombin receptor antagonism with vorapaxar: pharmacology and clinical trial development | Future Cardiology Platelet thrombin receptor antagonism with vorapaxar: pharmacology and clinical trial development | Future Cardiology](https://www.futuremedicine.com/cms/10.2217/fca.15.50/asset/images/medium/figure1.gif)
Platelet thrombin receptor antagonism with vorapaxar: pharmacology and clinical trial development | Future Cardiology
![Vorapaxar, a Platelet Thrombin Receptor Antagonist, in Acute Coronary Syndromes Kenneth W. Mahaffey, MD, on behalf of the TRACER Investigators and Committees. - ppt download Vorapaxar, a Platelet Thrombin Receptor Antagonist, in Acute Coronary Syndromes Kenneth W. Mahaffey, MD, on behalf of the TRACER Investigators and Committees. - ppt download](https://slideplayer.com/slide/13753195/85/images/2/Background+Vorapaxar%3A+First-in-class+Oral+PAR-1+inhibitor+Vorapaxar.jpg)
Vorapaxar, a Platelet Thrombin Receptor Antagonist, in Acute Coronary Syndromes Kenneth W. Mahaffey, MD, on behalf of the TRACER Investigators and Committees. - ppt download
![Platelet thrombin receptor antagonism with vorapaxar: pharmacology and clinical trial development | Future Cardiology Platelet thrombin receptor antagonism with vorapaxar: pharmacology and clinical trial development | Future Cardiology](https://www.futuremedicine.com/cms/10.2217/fca.15.50/asset/images/medium/figure2.gif)
Platelet thrombin receptor antagonism with vorapaxar: pharmacology and clinical trial development | Future Cardiology
![Vorapaxar for secondary prevention of thrombotic events for patients with previous myocardial infarction: a prespecified subgroup analysis of the TRA 2°P-TIMI 50 trial - The Lancet Vorapaxar for secondary prevention of thrombotic events for patients with previous myocardial infarction: a prespecified subgroup analysis of the TRA 2°P-TIMI 50 trial - The Lancet](https://www.thelancet.com/cms/attachment/4a9eb68c-575e-4aff-b70e-d04e85266a47/gr1_lrg.gif)
Vorapaxar for secondary prevention of thrombotic events for patients with previous myocardial infarction: a prespecified subgroup analysis of the TRA 2°P-TIMI 50 trial - The Lancet
![Pharmacodynamic Effects of Vorapaxar in Prior Myocardial Infarction Patients Treated With Potent Oral P2Y12 Receptor Inhibitors With and Without Aspirin: Results of the VORA‐PRATIC Study | Journal of the American Heart Association Pharmacodynamic Effects of Vorapaxar in Prior Myocardial Infarction Patients Treated With Potent Oral P2Y12 Receptor Inhibitors With and Without Aspirin: Results of the VORA‐PRATIC Study | Journal of the American Heart Association](https://www.ahajournals.org/cms/asset/ac79fef6-c949-454b-b30f-720cc1f33d78/jah35032-fig-0001.png)